RATIONALE: Bronchopulmonary dysplasia (BPD) and emphysema are characterized by arrested alveolar development or loss of alveoli; both are significant global health problems and currently lack effective therapy. Bone marrow-derived mesenchymal stem cells (BMSCs) prevent adult lung injury, but their therapeutic potential in neonatal lung disease is unknown. OBJECTIVES: We hypothesized that intratracheal delivery of BMSCs would prevent alveolar destruction in experimental BPD. METHODS: In vitro, BMSC differentiation and migration were assessed using co-culture assays and a modified Boyden chamber. In vivo, the therapeutic potential of BMSCs was assessed in a chronic hyperoxia-induced model of BPD in newborn rats. MEASUREMENTS AND MAIN RESULTS: In vitro, BMSCs developed immunophenotypic and ultrastructural characteristics of type II alveolar epithelial cells (AEC2) (surfactant protein C expression and lamellar bodies) when co-cultured with lung tissue, but not with culture medium alone or liver. Migration assays revealed preferential attraction of BMSCs toward oxygen-damaged lung versus normal lung. In vivo, chronic hyperoxia in newborn rats led to air space enlargement and loss of lung capillaries, and this was associated with a decrease in circulating and resident lung BMSCs. Intratracheal delivery of BMSCs on Postnatal Day 4 improved survival and exercise tolerance while attenuating alveolar and lung vascular injury and pulmonary hypertension. Engrafted BMSCs coexpressed the AEC2-specific marker surfactant protein C. However, engraftment was disproportionately low for cell replacement to account for the therapeutic benefit, suggesting a paracrine-mediated mechanism. In vitro, BMSC-derived conditioned medium prevented O(2)-induced AEC2 apoptosis, accelerated AEC2 wound healing, and enhanced endothelial cord formation. CONCLUSIONS: BMSCs prevent arrested alveolar and vascular growth in part through paracrine activity. Stem cell-based therapies may offer new therapeutic avenues for lung diseases that currently lack efficient treatments.
RATIONALE: Bronchopulmonary dysplasia (BPD) and emphysema are characterized by arrested alveolar development or loss of alveoli; both are significant global health problems and currently lack effective therapy. Bone marrow-derived mesenchymal stem cells (BMSCs) prevent adult lung injury, but their therapeutic potential in neonatal lung disease is unknown. OBJECTIVES: We hypothesized that intratracheal delivery of BMSCs would prevent alveolar destruction in experimental BPD. METHODS: In vitro, BMSC differentiation and migration were assessed using co-culture assays and a modified Boyden chamber. In vivo, the therapeutic potential of BMSCs was assessed in a chronic hyperoxia-induced model of BPD in newborn rats. MEASUREMENTS AND MAIN RESULTS: In vitro, BMSCs developed immunophenotypic and ultrastructural characteristics of type II alveolar epithelial cells (AEC2) (surfactant protein C expression and lamellar bodies) when co-cultured with lung tissue, but not with culture medium alone or liver. Migration assays revealed preferential attraction of BMSCs toward oxygen-damaged lung versus normal lung. In vivo, chronic hyperoxia in newborn rats led to air space enlargement and loss of lung capillaries, and this was associated with a decrease in circulating and resident lung BMSCs. Intratracheal delivery of BMSCs on Postnatal Day 4 improved survival and exercise tolerance while attenuating alveolar and lung vascular injury and pulmonary hypertension. Engrafted BMSCs coexpressed the AEC2-specific marker surfactant protein C. However, engraftment was disproportionately low for cell replacement to account for the therapeutic benefit, suggesting a paracrine-mediated mechanism. In vitro, BMSC-derived conditioned medium prevented O(2)-induced AEC2 apoptosis, accelerated AEC2 wound healing, and enhanced endothelial cord formation. CONCLUSIONS: BMSCs prevent arrested alveolar and vascular growth in part through paracrine activity. Stem cell-based therapies may offer new therapeutic avenues for lung diseases that currently lack efficient treatments.
Authors: Jacqueline C Chang; Ross Summer; Xi Sun; Kathleen Fitzsimmons; Alan Fine Journal: Am J Respir Cell Mol Biol Date: 2005-06-16 Impact factor: 6.914
Authors: Sébastien Bonnet; Evangelos D Michelakis; Christopher J Porter; Miguel A Andrade-Navarro; Bernard Thébaud; Sandra Bonnet; Alois Haromy; Gwyneth Harry; Rohit Moudgil; M Sean McMurtry; E Kenneth Weir; Stephen L Archer Journal: Circulation Date: 2006-05-30 Impact factor: 29.690
Authors: Mauricio Rojas; Jianguo Xu; Charles R Woods; Ana L Mora; Willy Spears; Jesse Roman; Kenneth L Brigham Journal: Am J Respir Cell Mol Biol Date: 2005-05-12 Impact factor: 6.914
Authors: Ping-Ping Kuang; Edgar Lucey; David C Rishikof; Donald E Humphries; Daniel Bronsnick; Ronald H Goldstein Journal: Am J Respir Cell Mol Biol Date: 2005-07-21 Impact factor: 6.914
Authors: Massimiliano Gnecchi; Huamei He; Nicolas Noiseux; Olin D Liang; Lunan Zhang; Fulvio Morello; Hui Mu; Luis G Melo; Richard E Pratt; Joanne S Ingwall; Victor J Dzau Journal: FASEB J Date: 2006-04 Impact factor: 5.191
Authors: Michael A Matthay; B Taylor Thompson; Elizabeth J Read; David H McKenna; Kathleen D Liu; Carolyn S Calfee; Jae Woo Lee Journal: Chest Date: 2010-10 Impact factor: 9.410
Authors: Anne Hilgendorff; Irwin Reiss; Harald Ehrhardt; Oliver Eickelberg; Cristina M Alvira Journal: Am J Respir Cell Mol Biol Date: 2014-02 Impact factor: 6.914
Authors: Michael A Matthay; Piero Anversa; Jahar Bhattacharya; Bruce K Burnett; Harold A Chapman; Joshua M Hare; Derek J Hei; Andrew M Hoffman; Stella Kourembanas; David H McKenna; Luis A Ortiz; Harald C Ott; William Tente; Bernard Thébaud; Bruce C Trapnell; Daniel J Weiss; Jason X-J Yuan; Carol J Blaisdell Journal: Am J Respir Crit Care Med Date: 2013-08-01 Impact factor: 21.405